WCLC 2016

04–07 December 2016 | Vienna, Austria

The 17th World Conference on Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) took place from 4-7 December, 2016 in Vienna, Austria.

The motto of the conference is “WCLC 2016 Together against Lung Cancer” and the three main topics were: active prevention, accurate diagnosis, and advanced care.

WCLC 2016

04–07 December 2016 | Vienna, Austria

The 17th World Conference on Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC) took place from 4-7 December, 2016 in Vienna, Austria.

The motto of the conference is “WCLC 2016 Together against Lung Cancer” and the three main topics were: active prevention, accurate diagnosis, and advanced care.

The nurse’s perspective on caring for lung cancer patients receiving immunotherapy 1:31
The nurse’s perspective on caring for lung cancer patients receiving immunotherapy
Rachel Thomas • 4 Dec 2016
The impact of p53 mutation on survival in EGFR-mutated NSCLC patients 1:13
The impact of p53 mutation on survival in EGFR-mutated NSCLC patients
Frank Griesinger • 4 Dec 2016
The nurse’s perspective on looking after lung cancer patients receiving immunotherapy 3:03
The nurse’s perspective on looking after lung cancer patients receiving immunotherapy
Rachel Thomas • 4 Dec 2016
How to monitor and manage immunotherapy related events in lung cancer 2:28
How to monitor and manage immunotherapy related events in lung cancer
Alexander Spira • 4 Dec 2016
FGFR driver genetic alterations in NSCLC 2:57
FGFR driver genetic alterations in NSCLC
Shirish Gadgeel
Angiogenesis inhibition in lung cancer 3:36
Angiogenesis inhibition in lung cancer
Maurice Pérol
How to maximize clinical benefits for patients with ALK-positive non-small cell lung cancer 3:53
How to maximize clinical benefits for patients with ALK-positive non-small cell lung cancer
Nicolas Girard
Challenges with biopsies in lung cancer diagnosis 1:26
Challenges with biopsies in lung cancer diagnosis
Gerhard Mostbeck
Osimertinib responses after rociletinib treatment of T790M-positive NSCLC 3:13
Osimertinib responses after rociletinib treatment of T790M-positive NSCLC
Shirish Gadgeel • 4 Dec 2016
Technology and social media in healthcare 2:52
Technology and social media in healthcare
Anne Ireland • 4 Dec 2016
Staging and diagnosis of lung cancer: methods and challenges 1:52
Staging and diagnosis of lung cancer: methods and challenges
Gerhard Mostbeck • 4 Dec 2016
How do side effects from immunotherapy differ from side effects from chemotherapy in lung cancer? 0:37
How do side effects from immunotherapy differ from side effects from chemotherapy in lung cancer?
Alexander Spira • 4 Dec 2016
Overview of the world of EGFR mutant lung cancers 3:38
Overview of the world of EGFR mutant lung cancers
Barbara Melosky • 4 Dec 2016
Anamorelin for cachexia for patients with NSCLC 1:09
Anamorelin for cachexia for patients with NSCLC
David Currow • 4 Dec 2016
E-cigarettes and their health impacts 3:53
E-cigarettes and their health impacts
Charlotta Pisinger • 4 Dec 2016
Atezolizumab with erlotinib in combination treatment for EGFR mutant NSCLC 2:36
Atezolizumab with erlotinib in combination treatment for EGFR mutant NSCLC
Charles Rudin • 4 Dec 2016

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals